Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMR0EVN)

• Drug Name: Alpha-D-Glucose-6-Phosphate Drug Info
• Synonyms: 6-O-phosphono-alpha-D-glucopyranose; UNII-03JQ7I74CO; 03JQ7I74CO; CHEBI:17665; alpha-D-Glucopyranose, 6-(dihydrogen phosphate); alpha-D-glucopyranose 6-(dihydrogen phosphate); 15209-11-7; alpha-D-glucopyranose 6-phosphate; G6P; 1gpy; Epitope ID:144999; SCHEMBL6598; AC1L971Q; NBSCHQHZLSJFNQ-DVKNGEFBSA-N; CHEBI:136602; ZINC3875375; DB02007; C00668; WURCS=2.0/1,1,0/[a2122h-1a_1-5_6*OPO/3O/3=O]/1/

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 439284
  ChEBI ID: CHEBI:17665
  CAS Number: CAS 15209-11-7
  TTD Drug ID: DMR0EVN

Molecule-Related Drug Atlas

Drug(s) Targeting Bacterial Glucosamine-6-phosphate synthase (Bact glmS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glucose-6-Phosphate	DMKY1L4	N. A.	N. A.	Phase 1	[1]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
2-(N-Morpholino)-Ethanesulfonic Acid	DMZVHSB	Discovery agent	N.A.	Investigative	[1]
Glutamine Hydroxamate	DMT7K0U	Discovery agent	N.A.	Investigative	[1]
2-Deoxy-2-Amino Glucitol-6-Phosphate	DMBMK4T	Discovery agent	N.A.	Investigative	[1]
Glucosamine 6-Phosphate	DMY590Q	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Aldose reductase (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Epalrestat	DM5OGK0	Diabetic neuropathy	8C0Z	Approved	[2]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[3]
Fidarestat	DMZL1I8	Diabetic complication	5A2Y	Phase 3	[4]
Ranirestat	DMD5QRS	Diabetic neuropathy	8C0Z	Phase 3	[5]
CONTIGOSIDE B	DMX9V8K	Thrombosis	DB61-GB90	Phase 2/3	[6]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[5]
BNV-222	DMYFQJL	Diabetic neuropathy	8C0Z	Phase 2/3	[7]
LIDORESTAT	DMA0RI9	Diabetic complication	5A2Y	Phase 2	[8]
QR-333	DMKVIWM	Diabetic neuropathy	8C0Z	Phase 2	[9]
ADMVA	DM819CO	Diabetic complication	5A2Y	Phase 2	[5]

Drug(s) Targeting Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[1]
D-Mannose 1-Phosphate	DM7O1IW	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Mannose-6-Phosphate	DM3NCM1	Discovery agent	N.A.	Investigative	[1]
Alpha-D-Glucose-1-Phosphate	DMU36HT	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Glycogen phosphorylase muscle form (GP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[10]
JTT-651	DMGP42Q	Type-2 diabetes	5A11	Discontinued in Phase 1	[11]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[1]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[1]
Indirubin-5-sulfonate	DM08VHZ	Discovery agent	N.A.	Investigative	[1]
Inosinic Acid	DMLR86H	Discovery agent	N.A.	Investigative	[1]
N'-Pyridoxyl-Lysine-5'-Monophosphate	DM3ZHBO	Discovery agent	N.A.	Investigative	[1]
OLEANOLIC_ACID	DMWDMJ3	Discovery agent	N.A.	Investigative	[12]
Oleanonic acid	DMYPJC3	Discovery agent	N.A.	Investigative	[12]
Nojirimycine Tetrazole	DMYZRTB	Discovery agent	N.A.	Investigative	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aldose reductase (AKR1B1)	TTFBNVI	ALDR_HUMAN	Inhibitor	[1]
Bacterial Glucosamine-6-phosphate synthase (Bact glmS)	TTC67I0	GLMS_ECOLI	Inhibitor	[1]
Glycogen phosphorylase muscle form (GP)	TTZHY6R	PYGM_HUMAN	Inhibitor	[1]
Pseudomonas Phosphomannomutase/phosphoglucomutase (Pseudo algC)	TTLP3GX	ALGC_PSEAE	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complications. 2001 Sep-Oct;15(5):241-4.
• [3] Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin. Biochem Pharmacol. 1983 Jul 1;32(13):1995-8.
• [4] Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001 Oct;24(10):1776-82.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2768).
• [6] Effect of Polygonum hydropiper sulfated flavonoids on lens aldose reductase and related enzymes. J Nat Prod. 1996 Apr;59(4):443-5.
• [7] ClinicalTrials.gov (NCT02332005) 12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study (DE-DPN). U.S. National Institutes of Health.
• [8] Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors ... J Med Chem. 2005 May 5;48(9):3141-52.
• [9] A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report. J Diabetes Complications. 2005 Sep-Oct;19(5):247-53.
• [10] Synthesis of 3-deoxypentacyclic triterpene derivatives as inhibitors of glycogen phosphorylase. J Nat Prod. 2009 Aug;72(8):1414-8.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026877)
• [12] Naturally occurring pentacyclic triterpenes as inhibitors of glycogen phosphorylase: synthesis, structure-activity relationships, and X-ray crystal... J Med Chem. 2008 Jun 26;51(12):3540-54.
• [13] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.